reports
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
WLK WESTLAKE CHEMICAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TGTX TG THERAPEUTICS INC.
SIG SIGNET JEWELERS LIMITED
SAIA SAIA INC.
RICK RCI HOSPITALITY HOLDINGS
RCKY ROCKY BRANDS
PFGC PERFORMANCE FOOD GROUP COMPANY
MKSI MKS INSTRUMENTS INC.
IRDM IRIDIUM COMMUNICATIONS INC.
IPAR INTER PARFUMS INC.
IDXX IDEXX LABORATORIES INC.
FRGI FIESTA RESTAURANT GROUP INC.
FOXF FOX FACTORY HOLDING CORP.
FGEN FIBROGEN INC.
CPS COOPER-STANDARD HOLDINGS INC.
CNCE CONCERT PHARMACEUTICALS
AEIS ADVANCED ENERGY INDUSTRIES INC.
EVER EVER GOTESCO RESOURCES & HOLDINGS INC.
MGM MGM RESORTS INTERNATIONAL
ODFL OLD DOMINION FREIGHT LINE INC.
THO THOR INDUSTRIES INC.
X UNITED STATES STEEL CORPORATION
CLF CLEVELAND-CLIFFS INC
DCPH DECIPHERA PHARMACEUTICALS INC.
RYTM RHYTHM PHARMACEUTICALS
WHD CACTUS INC
LOVE LOVESAC
TROX TRONOX HOLDINGS PLC
FOX FOX CORPORATION CLASS B
ZYXI ZYNEX
NOV NOV INC.
XPOF XPONENTIAL FITNESS
RAIN INC.
SGHT RAIN THERAPEUTICS INC
ROIV SIGHT SCIENCES INC
OMGA ROIVANT SCIENCES LTD
KMPH OMEGA THERAPEUTICS INC
GBLI KEMPHARM INC
GBLI HOLDINGS LLC
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
BLUE BLUEBIRD BIO INC.
SRDX SURMODICS INC.
MKTX MARKETAXESS HOLDINGS INC.
LUNA LUNA INNOVATIONS
IPAR INTER PARFUMS INC.
HES HESS CORPORATION
CNCE CONCERT PHARMACEUTICALS
CLMT CALUMET SPECIALTY PRODUCTS PARTNERS L.P.
CHGG CHEGG INC.
PATK PATRICK INDUSTRIES INC.
MPC. MADISON PACIFIC PROPERTIES INC. CL B
GRL TOREX GOLD RESOURCES INC.
ACLS AXCELIS TECHNOLOGIES INC.
ETH ETHAN ALLEN INTERIORS INC.
MAT MATTEL INC.
NRP NATURAL RESOURCE PARTNERS L.P.
USFD US FOODS HOLDING CORP.
INFU INFUSYSTEMS HOLDINGS INC.
INTT INTEST CORP.
PLBC PLUMAS BANCORP
LW LAMB WESTON HOLDINGS INC.
ANAB ANAPTYSBIO INC.
DCPH DECIPHERA PHARMACEUTICALS INC.
KRYS KRYSTAL BIOTECH INC
ETNB 89BIO
FRG FRANCHISE GROUP
COGT COGENT BIOSCIENCES INC
JAKK JAKKS PACIFIC INC.
CAG ANGIANG PORT
XPOF XPONENTIAL FITNESS
RAIN INC.
ATXS RAIN THERAPEUTICS INC
ACLX ASTRIA THERAPEUTICS INC
OMGA ARCELLX INC
ADEA OMEGA THERAPEUTICS INC
XPERI HLDG CORP
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
ORMP ORAMED PHARMACEUTICALS
MGNX MACROGENICS INC.
HCI HCI GROUP INC.
CPS COOPER-STANDARD HOLDINGS INC.
CNCE CONCERT PHARMACEUTICALS
CLMT CALUMET SPECIALTY PRODUCTS PARTNERS L.P.
CBAY CYMABAY THERAPEUTICS INC.
ARWR ARROWHEAD PHARMACEUTICALS INC.
ALDX ALDEYRA THERAPEUTICS
SMMT GOLDEN EAGLE ENERGY
ATEC ALPHATEC HOLDINGS INC.
FI FRANK'S INTERNATIONAL NV
WVE WAVE LIFE SCIENCES
NWLI NATIONAL WESTERN LIFE GROUP - CL A
PTGX PROTAGONIST THERAPEUTICS
BOOM DMC GLOBAL INC
NINE NINE ENERGY SERVICE INC
PRVB PROVENTION BIO INC
STRO SUTRO BIOPHARMA
HROW HARROW HEALTH INC.
PDSB PDS BIOTECHNOLOGY CORPORATION
CABA CABALETTA BIO
AKRO AKERO THERAPEUTICS
ALT ALTIMMUNE INC
RNA AVIDITY BIOSCIENCES
VRT VERTIV HOLDINGS CO (A)
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
HURN HURON CONSULTING GROUP INC.
ESPR ESPERION THERAPEUTICS INC.
CNCE CONCERT PHARMACEUTICALS
A AGILENT TECHNOLOGIES INC.
ARCLK ARCELIK A.S.
CCRN CROSS COUNTRY HEALTHCARE INC.
SJT SAN JUAN BASIN ROYALTY TRUST
MYOV MYOVANT SCIENCE
MRSN MERSANA THERAPEUTICS
VERU VERU
HHS HARTE-HANKS INC.
COGT COGENT BIOSCIENCES INC
JAKK JAKKS PACIFIC INC.
HOWL WEREWOLF THERAPEUTICS INC
LYEL LYELL IMMUNOPHARMA INC
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
SM SM ENERGY COMPANY
MOD MODINE MANUFACTURING COMPANY
MMYT MAKEMYTRIP LTD.
EZPW EZCORP INC. CLASS A
ENS ENERSYS
DLTR DOLLAR TREE INC.
DDS DILLARD'S INC. CLASS A
CNCE CONCERT PHARMACEUTICALS
ALB ALBEMARLE CORPORATION
MG/CN MAGNA INTERNATIONAL INC.
PLAB PHOTRONICS INC.
DXC DXC TECHNOLOGY CO.
PLYA PLAYA HOTELS & RESORTS
1A88 GRINDROD SHIPPING HOLDINGS
MEC MAYVILLE ENGINEERING
OI O-I GLASS INC
DLO DLOCAL LTD
UDMY UDEMY INC
MCG MEMBERSHIP COLLECTIVE GRP INC
LVLU LULUS FASHION LOUNGE HLDGS INC
1 director bought
A director at Concert Pharmaceuticals Inc bought 10,000 shares at 5.901USD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...
- GlobalData Department
Concert Pharmaceuticals Inc (CNCE) - Pharmaceuticals & Healthcare - De...
Summary Concert Pharmaceuticals Inc (Concert Pharmaceuticals) is a clinical stage biotechnology company which discovers and develops small molecule drugs. The company develops its products using its deuterated chemical entity (DCE) platform to develop novel therapeutics for autoimmune and inflammatory diseases, pulmonary diseases, and disorders of central nervous system (CNS). Its product pipeline includes CTP-543 (deuterated ruxolitinib) for alopecia areata; AVP-786 (deuterated dextromethorpha...
Concert Pharmaceuticals Reports First Quarter 2018 Financial Results
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of 2018. “Concert has begun 2018 with strong momentum as our pipeline of first-in-class drug candidates for serious diseases is progressing in important efficacy trials, with the first data read out later this year for CTP-543,” said Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals. “We look forward to the progression of multiple Concert-discovered co...
Concert Pharmaceuticals to Report First Quarter 2018 Financial Results...
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its first quarter 2018 financial results on Thursday, May 3, 2018, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss first quarter financial results and provide a business update. Individuals interested in participating in the call should dial (855) 354-1855 (U.S. and Canada) or (484) 365-2865 (International). In addition, the Company t...
Concert Pharmaceuticals Completes Enrollment in Phase 2a Trial of CTP-...
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed patient enrollment of its Phase 2a trial evaluating CTP-543 for the treatment of moderate-to-severe alopecia areata. The Company expects to report topline data from the 4 mg and 8 mg cohorts of the Phase 2a trial in the fourth quarter of 2018. Additionally, a Phase 2b clinical trial is expected to begin in 2019. “The speed with which we enrolled the trial speaks to the significant unmet need for alopec...
Concert Pharmaceuticals Present at Upcoming Investor Conferences
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the following upcoming investor conferences: The Cowen 38th Annual Healthcare Conference on March 13, 2018 at 11:20 a.m. ET in Boston; The Oppenheimer 28th Annual Healthcare Conference on March 20, 2018 at 1:00 p.m. ET in New York, NY; and The H.C. Wainwright Global Life Sciences Conference on April 9-10, 2018 in Monaco. ...
Concert Pharmaceuticals Reports Year Ended 2017 Financial Results
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today reported financial results for the year ended December 31, 2017, as well as provided an update on its product pipeline and corporate activities. “Our focus for Concert in 2018 centers around pipeline advancement, notably CTP-543 for moderate-to-severe alopecia areata, and our newly announced development candidate, CTP-692, for adjunctive treatment of schizophrenia. These differentiated product candidates were created with our deuteriu...
Concert Pharmaceuticals Announces Advancement of Novel Drug Candidate ...
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the next development candidate in its product pipeline with the selection of CTP-692, a novel drug for adjunctive treatment of schizophrenia, a devastating, chronic illness with significant unmet need. CTP-692 is a deuterated form of D-serine, an endogenous, required co-agonist of the N-methyl-D-aspartate (NMDA) receptor. NMDA receptor hypofunction is believed to contribute to the pathophysiology of schizophrenia and enhancement of ...
Concert Pharmaceuticals to Report Full Year 2017 Results on March 1, 2...
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the year ended December 31, 2017, on Thursday, March 1, 2018, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss 2017 financial results and provide a business update. Individuals interested in participating in the call should dial (855) 354-1855 (U.S. and Canada) or (484) 365-2865 (International). A live webcast...
Concert Pharmaceuticals Announces Initiation of Enrollment in Second C...
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated enrollment of the second cohort of its Phase 2a clinical trial evaluating CTP-543. Concert is developing CTP-543 for the treatment of moderate-to-severe alopecia areata, an autoimmune disorder in which the immune system attacks hair follicles, resulting in patchy or complete hair loss. CTP-543 is a deuterium-modified analog of ruxolitinib, a Janus Kinase (JAK) inhibitor. An independent Data Monitoring ...
FDA Grants Fast Track Designation to Concert Pharmaceuticals’ CTP-54...
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for CTP-543, a novel, oral Janus kinase (JAK) inhibitor for the treatment of moderate-to-severe alopecia areata, an autoimmune disorder in which the immune system attacks hair follicles, resulting in patchy or complete hair loss. Fast Track designation is a process designed to facilitate the development and expedite the review of new therapi...
Concert Pharmaceuticals Announces Patent Trial and Appeal Board Did No...
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has decided not to grant the Company’s Post Grant Review (PGR) petition challenging the validity of U.S. Patent No. 9,662,335 (referred to as the ’335 patent) assigned to Incyte Pharmaceuticals. “We are disappointed that the PTAB has denied our petition on the ’335 patent. This decision does not prohibit us from challenging the validity of...
Concert Pharmaceuticals Announces the Appointment of Marc Becker as Ch...
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the appointment of Marc Becker as Chief Financial Officer, effective January 4, 2018. Mr. Becker is a seasoned financial executive with more than 15 years of experience in the biotechnology industry. “We are pleased to welcome Marc to the Concert team,” said Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals. “Marc further strengthens our management team with his financial and operational ba...
Concert Pharmaceuticals to Be Added to NASDAQ Biotechnology Index
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI) effective prior to the market open on Monday, December 18, 2017. The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ-listed securities that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. The NASDAQ Biotechnology Index is re-ranked annually. For ...
Concert Pharmaceuticals Reports Third Quarter 2017 Financial Results a...
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the third quarter of 2017. “This is an exciting time for our deuterium-based chemistry as we continue to demonstrate our technology’s ability to meaningfully improve the clinical properties of existing medicines. The CTP-656 program and subsequent asset purchase agreement with Vertex Pharmaceuticals is a great example of leveraging our platform to rapidly create significant value,” said Roger Tung, Ph.D...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.